<div>
  <ul>
    <li>
      <p>
        Glooko, a remote patient monitoring and diabetes care platform, has acquired French diabetes care platform DIABNEXT as part of its plans to
        <b> </b>
        expand its platform reach across the globe. This marks the company&rsquo;s second acquisition so far in 2022. It previously acquired xbird, an AI-powered diabetes care tool, in January 2022.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The French company&rsquo;s mobile app tracks and monitors patient diabetes data to support remote care. Following the acquisition, DIABNEXT&rsquo;s employees will join Glooko&rsquo;s Paris office, and Laurent Nicolas, the former CEO of DIABNEXT, will lead its operations in France as managing director.&nbsp;
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market. The acquisition will help DIABNEXT scale its operations into more regions and expand its remote patient monitoring services.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://glooko.com/news_reg/glooko-acquires-diabnext-to-expand-diabetes-offerings-in-france/">
      Company press release
    </a>
  </p>
  <p>
    <a href="https://hitconsultant.net/2022/03/16/glooko-acquires-diabnext/">
      HIT Consultant
    </a>
  </p>
  <p>
    <a href="https://www.mobihealthnews.com/news/glooko-acquires-fellow-diabetes-management-company-diabnext-and-more-digital-health-briefs">
      Mobi Health News
    </a>
  </p>
</div>


Preventive Healthcare

Glooko acquires DIABNEXT to expand platform offering in France

ANALYST_QUICK_TAKE

<div>
 
 <p>The FDA has broadened the approved age range for Theranica's Nerivio remote electrical neuromodulation device, now including patients aged eight and above. Prior to this update, the device was only authorized for patients aged 12 and upwards. This device is distinguished as the first FDA-cleared non-pharmaceutical option for both the acute and preventive treatment of migraines specifically for children in this newly approved age bracket.</p>
 <p>Support for this extended approval was partially sourced from real-world data gathered from a study centred around children aged between six and eleven years. The research noted that 72.2% of studied patients experienced consistent alleviation of headaches, whilst 83.3% of patients indicated repeated relief from functional disability roughly two hours after undergoing treatment. No negative side-effects were reported in correlation to the use of the device in this study.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> Nerivio received FDA approval for treating acute migraines in May 2019, and, in <a href="https:<br>
//sp-edge.com/updates/2117"> January 2021 </a> , the firm obtained FDA clearance to market its product as a treatment for episodic or chronic migraines while expanding treatment to adolescents. Its closest competitor, gammaCore from <a href="https:<br>
//sp-edge.com/companies/126846"> electroCore </a> , is the only other device approved for adolescents.</p>

Theranica's Nerivio receives expanded FDA approval for migraine treatment in children

PROMINENT_CATEGORY

<div>
 
 <p>In its Q3 2024 financial update, Movano Health reported being in the final stage of FDA review for its EvieMED Ring, a device that combines pulse oximetry with wellness metrics related to sleep, activity, and health symptom logging. The company recently provided a comprehensive response to further inquiries about its medical features.</p>
 <p>Movano Health is already planning for B2B opportunities pending FDA approval and is in talks with a large healthcare entity about a Q1 2025 pilot program. The pilot will leverage the EvieMED Ring for metabolic solutions in managing chronic diseases.</p>
 <p>The company's operating loss in Q3 2024 was USD 7.4 million, a notable reduction from the USD 9.1 million loss recorded in Q3 2023, as indicated in the Q3 financial update.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> After launching the Evie Ring in <a href="https:<br>
//sp-edge.com/updates/23385"> November 2023 </a> for USD 269 without a subscription fee, Movano Health shipped 339 units in Q3 2024, reflecting early market traction. Later, the company raised USD 24 million in private placement in <a href="https:<br>
//sp-edge.com/updates/28136"> April 2024 </a> to support its ongoing operations.&nbsp;</p>

Movano Health provides update on FDA application for EvieMED ring

<div>
 <p>Beta Bionics, a provider of diabetes management solutions, has landed USD 60 million in a Series E funding round. The investment was led by Wellington Management and included participation from Eventide Asset Management, RTW Investments, Sands Capital, Soleus Capital, Omega Funds, Perceptive Advisors, and Marshall Wace.</p>
 <p>This funding will be used to boost commercialization of the company's main product, the iLet Bionic Pancreas, and further develop its product pipeline. The goal is to enhance health outcomes for individuals with diabetes and other glycemic dysregulation conditions.</p>
 <p>The iLet Bionic Pancreas, Beta Bionics's flagship product, is a self-regulating insulin delivery system that determines and adapts insulin doses automatically. To start operating, it only requires the user's weight as input.</p>
</div> <p><b>Analyst QuickTake:<br>
 </b> The company last raised <a href="https:<br>
//sp-edge.com/updates/21628"> USD 100 million </a> in an August 2023 Series D round to expand access to the iLet Bionic Pancreas across the US. With the latest funding, the company seems to expand its horizons to reach more patients and increase its market share.</p>

Beta Bionics raises USD 60 million in Series E funding to expand iLet Bionic Pancreas commercialization and develop treatments

<div>
 
 <p>Direct primary care provider Forward has announced a sudden cessation of all its operations. This includes closing all their establishments and discontinuing their mobile application, impacting roughly 200 of their workforce.</p>
 <p>Forward will assist patients in accessing their medical records and recommend resources for locating new providers. For patient assistance, the organization's medical team will continue to be reachable via email until December 13, 2024.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> In <a href="https:<br>
//sp-edge.com/updates/24021"> November 2023 </a> , Forward raised USD 100 million in a Series E funding round and launched AI-based CarePods in multiple cities, with plans to deploy 3,200 units in 2024. While the reason for the shutdown is unclear, it appears the company faced challenges in scaling as planned and achieving its goal of replacing traditional doctor’s offices with AI-driven solutions.</p>

Forward Healthcare shuts down after eight years of operations

<div>
 <p>Oshi Health, a virtual gastrointestinal (GI) care clinic, has entered a partnership with CuraLinc Healthcare, a provider of mental health services. The objective of this collaboration is to enhance employee wellness programs via Oshi Health's Partner Network.</p>
 <p>One of the key agenda is to focus on the interrelation between mental health and GI disorders. This will be done by incorporating Oshi Health's virtual care services for diseases such as IBS, Crohn's Disease, and GERD into CuraLinc's mental health offerings.&nbsp;</p>
</div> <p><b>Analyst QuickTake:<br>
 </b> Over the years, the company has been expanding access to its platform through alliances with <a href="https:<br>
//sp-edge.com/updates/17587"> Aetna </a> , <a href="https:<br>
//sp-edge.com/updates/9146"> Firefly Health, </a> and <a href="https:<br>
//www.mobihealthnews.com/news/solera-health-adds-new-gut-health-offerings"> Solera Health </a> . The recent partnership with CuraLinc supports Oshi Health’s expansion in GI care, now reaching over 40 million people. <a href="https:<br>
//sp-edge.com/updates/34898"> Recently </a> , the company also raised USD 60 million to further strengthen its position.</p>

Oshi Health partners with CuraLinc Healthcare for mental and digestive health services

<div>
 <p>Cardiac monitoring systems manufacturer, iRhythm Technologies, has been granted a second FDA 510(k) clearance for design alterations and labeling updates to its Zio AT wearable cardiac monitoring system. This clearance was received only one week after gaining the first 510(k) clearance for design changes.</p>
 <p>iRhythm has intensified its efforts in boosting its quality management system. The company has grown its regulatory and quality-related staff from 20 to over 100, appointed a new leader for quality management, and partnered with a consulting firm to facilitate internal audits. Additionally, the firm has decided to postpone its FDA submission for the upcoming Zio MCT device till the third quarter of 2025, planning for a launch in the following year.</p>
</div> <p><b>Analyst QuickTake:<br>
</b> In May 2023, the FDA <a href="https:<br>
//cardiovascularbusiness.com/topics/healthcare-management/healthcare-policy/fda-warning-letter-irhythm"> issued </a> a warning letter to iRhythm Technologies, highlighting serious compliance issues regarding its Zio AT mobile cardiac telemetry device. The recent clearance addresses design modifications and required labeling updates regarding manufacturing facility issues this warning letter highlights.</p>

iRhythm receives FDA 510(k) clearance for Zio AT cardiac monitor updates

<div>
 <p>Diagnostic tool provider Bright Uro has raised USD 32 million in Series A funding. The funding round was led by Laborie Medical Technologies and included participation from University of California (UC Investments), Freepoint Capital Group, and Laurelin Investors.</p>
 <p>The raised funds will aid the expected 2025 launch of the Glean Urodynamics System, help expand manufacturing capacity, and support R&amp;D activities for future development. The Glean Urodynamics System, which is waiting for FDA approval, aims to facilitate wireless, catheter-free urodynamics monitoring for patients suffering from lower urinary tract symptoms.</p>
</div>

Bright Uro raises USD 32 million in Series A funding to support product launch

<div>
 
 <p>DarioHealth, a digital therapeutics platform, has entered a partnership with a regional health plan to deliver cardiometabolic solutions to the health plan's Medicaid members.</p>
 <p>This agreement allows Dario to incorporate its digital therapeutics platform into the care plans of approximately 10,000 Medicaid participants. This marks Dario's third Medicaid client acquisition and its eighth health plan contract overall. The partnership will initially roll out as a pilot program, aimed at tailoring member experiences across various support platforms and channels.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Earlier this <a href="https:<br>
//sp-edge.com/updates/34315"> month </a> , DarioHealth partnered with a national Medicare Advantage health plan to offer digital mental health benefits via its Twill by Dario platform. These partnerships underscore Dario's focus on reaching diverse populations and expanding its revenue in digital health.</p>

DarioHealth partners with regional health plan to provide cardiometabolic solutions for Medicaid members

<div>
 <p>Remote patient monitoring (RPM) platform CoachCare has acquired Dedica Health, a fellow RPM company, to enhance its service portfolio. </p>
 <p>This acquisition is strategically aimed to broaden CoachCare's capabilities in remote patient monitoring and chronic care management. As part of the acquisition, Dr. Menachem Wakslak, the founder of Dedica, will serve as a senior advisor to the CEO at CoachCare.</p>
 <p>Dedica Health, established in 2021, focuses on providing primary care and cardiology remote patient monitoring solutions. Their solutions offer constant patient data monitoring from connected devices in between office visits, providing clinical insights that allow timely interventions to prevent unnecessary ER visits and hospital admissions.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> This acquisition is CoachCare’s first in 2024, furthering its growth by expanding capabilities across medical specialties. In 2023, the company acquired NVOLVE, Alertive, WebCareHealth, and Verustat, broadening its remote patient monitoring services across pain, cardiology, nephrology, orthopedics, and primary care to support a wider range of health conditions.</p>

CoachCare acquires Dedica Health to expand offering

<div>
 
 <p>AI-based platform, Viz.ai, has boosted its lung disease software functionalities. The updated software leverages natural language processing (NLP) and imaging AI to optimize patient screening and tracking for lung diseases.</p>
 <p>The advanced software will extract clinical data from electronic health records (EHR) and detect and supervise patients with lung disease. It will be incorporated into Viz.ai's current platform to expedite the care process, intending to diminish the treatment time and enhance patient outcomes.</p>
 
</div>

All Updates

Glooko acquires DIABNEXT to expand platform offering in France

Theranica's Nerivio receives expanded FDA approval for migraine treatment in children

Movano Health provides update on FDA application for EvieMED ring

Beta Bionics raises USD 60 million in Series E funding to expand iLet Bionic Pancreas commercialization and develop treatments

Forward Healthcare shuts down after eight years of operations

Oshi Health partners with CuraLinc Healthcare for mental and digestive health services

iRhythm receives FDA 510(k) clearance for Zio AT cardiac monitor updates

Bright Uro raises USD 32 million in Series A funding to support product launch

DarioHealth partners with regional health plan to provide cardiometabolic solutions for Medicaid members

CoachCare acquires Dedica Health to expand offering

Viz.ai expands into lung disease software with NLP capabilities

Preventive Healthcare

Glooko acquires DIABNEXT to expand platform offering in France

Contact us